博晖创新(300318.SZ)：联合申报的冻干b型流感嗜血杆菌结合疫苗获得药物临床试验批准

Core Viewpoint - The announcement indicates that Bohui Innovation's subsidiary, Langfang Bohui, in collaboration with Beijing Baihui Biotechnology, has received approval from the National Medical Products Administration for clinical trials of a lyophilized Hib conjugate vaccine [1] Group 1: Company Developments - Bohui Innovation's subsidiary, Langfang Bohui, is involved in the development of a lyophilized Hib conjugate vaccine [1] - The vaccine aims to stimulate immune response to prevent invasive infections caused by Hib, such as meningitis, pneumonia, sepsis, cellulitis, arthritis, and epiglottitis [1] Group 2: Industry Context - The lyophilized Hib conjugate vaccine is developed using purified Hib capsular polysaccharide antigen combined with tetanus toxoid to create a polysaccharide-protein conjugate [1] - Currently, the only other manufacturer of lyophilized Hib conjugate vaccine in China is Beijing Minhui Biotechnology [1]